|
US6451308B1
(en)
*
|
1996-04-26 |
2002-09-17 |
Beth Israel Deaconess Medical Center |
Antagonists of interleukin-15
|
|
EP1049773B1
(en)
|
1998-01-22 |
2007-07-25 |
Btg International Limited |
Inhibition of cytokine production
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
WO2000001851A1
(en)
*
|
1998-07-07 |
2000-01-13 |
Hisamitsu Pharmaceutical Co., Inc. |
Antisense oligonucleotides targeted to il-15
|
|
GB9814892D0
(en)
*
|
1998-07-10 |
1998-09-09 |
Kennedy Rheumatology Inst |
Treatment of celiac disease
|
|
US5985663A
(en)
*
|
1998-11-25 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of interleukin-15 expression
|
|
WO2001002003A1
(en)
*
|
1999-07-06 |
2001-01-11 |
Bulfone Paus Silvia |
Method of treating psoriasis with il-15 antagonist
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
BR0110779A
(pt)
*
|
2000-05-12 |
2005-01-11 |
Beth Israel Hospital |
Composições e métodos para adquirir supressão imunológica
|
|
ATE427318T1
(de)
*
|
2000-09-14 |
2009-04-15 |
Beth Israel Hospital |
Modulierung von il-2 und il-15 vermittelten t zellantworten
|
|
US20060134140A1
(en)
*
|
2001-04-12 |
2006-06-22 |
Dana Lasko |
Compositions and methods for treating tumor spreading
|
|
US7718196B2
(en)
*
|
2001-07-02 |
2010-05-18 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Rapamycin-resistant T cells and therapeutic uses thereof
|
|
AU2002320630A1
(en)
|
2001-07-17 |
2003-03-03 |
University Of Florida |
Detecting and treating reproductive tract disorders
|
|
US7329405B2
(en)
*
|
2001-08-23 |
2008-02-12 |
Genmab A/S |
Human antibodies specific for interleukin 15 (IL-15)
|
|
IL160358A0
(en)
*
|
2001-08-23 |
2004-07-25 |
Genmab As |
Human antibodies specific for interleukin 15 (il-15)
|
|
US7247304B2
(en)
*
|
2001-08-23 |
2007-07-24 |
Genmab A/S |
Methods of treating using anti-IL-15 antibodies
|
|
US20030049694A1
(en)
*
|
2001-09-10 |
2003-03-13 |
Chung-Hsiun Wu |
Production of fusion proteins and use for identifying binding molecules
|
|
US6800462B2
(en)
*
|
2001-09-10 |
2004-10-05 |
Abgenomics Corporation |
Production of recombinant proteins in vivo and use for generating antibodies
|
|
US20060236411A1
(en)
*
|
2002-10-14 |
2006-10-19 |
Ingeborg Dreher |
Antagonists il-15
|
|
CN100427597C
(zh)
*
|
2003-11-26 |
2008-10-22 |
中国医学科学院基础医学研究所 |
可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法
|
|
EP1718670B1
(en)
*
|
2004-02-27 |
2011-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity
|
|
WO2005100394A2
(en)
*
|
2004-04-14 |
2005-10-27 |
F. Hoffmann-La Roche Ag |
PURIFIED INTERLEUKIN-15/Fc FUSION PROTEIN AND PREPARATION THEREOF
|
|
JP2005309295A
(ja)
*
|
2004-04-26 |
2005-11-04 |
Nec Corp |
光増幅素子、光増幅装置および光増幅システム
|
|
US20060057680A1
(en)
*
|
2004-08-11 |
2006-03-16 |
Zheng Xin X |
Mutant interleukin-15 polypeptides
|
|
CU23472A1
(es)
*
|
2004-09-17 |
2009-12-17 |
Ct Ingenieria Genetica Biotech |
Péptido antagonista de la interleucina-15
|
|
JP2008515896A
(ja)
*
|
2004-10-05 |
2008-05-15 |
オクスナー クリニック ファウンデーション |
Ｉｌ−１５によるｂ細胞増殖の増強
|
|
EP3263581B2
(en)
|
2005-05-17 |
2025-07-09 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
US9163257B2
(en)
*
|
2005-06-20 |
2015-10-20 |
Cadila Healthcare Limited |
Expression vector and methods of producing high levels of proteins
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
EP2366787B1
(en)
|
2006-01-13 |
2019-12-11 |
The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services |
Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
|
|
EP1921452A1
(en)
*
|
2006-11-08 |
2008-05-14 |
Medizinische Hochschule Hannover |
Method for the diagnosis of leukemia
|
|
US20110020269A1
(en)
*
|
2007-05-08 |
2011-01-27 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for modifying t cell immune responses and inflammation
|
|
DK2160401T3
(da)
*
|
2007-05-11 |
2014-10-20 |
Altor Bioscience Corp |
Fusionsmolekyler og il-15-varianter
|
|
NZ582330A
(en)
|
2007-06-27 |
2012-05-25 |
Marinepolymer Tech Inc |
COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
|
|
CU23716A1
(es)
|
2008-09-30 |
2011-10-05 |
Ct Ingenieria Genetica Biotech |
Péptido antagonista de la actividad de la interleucina-15
|
|
CA2766839A1
(en)
|
2009-07-30 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Enzymatic antibody processing
|
|
WO2011020047A1
(en)
|
2009-08-14 |
2011-02-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
SG10201605397PA
(en)
|
2011-07-01 |
2016-08-30 |
Hoffmann La Roche |
Method For Separation Of Monomeric Polypeptides From Aggregated Polypeptides
|
|
DK2986312T3
(da)
|
2013-04-19 |
2022-02-14 |
Cytune Pharma |
Cytokinafledt behandling med reduceret vaskulært lækagesyndrom
|
|
CA2918119C
(en)
*
|
2013-07-19 |
2022-11-29 |
Centre Hospitalier Regional Universitaire De Montpellier |
Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases
|
|
KR101440915B1
(ko)
|
2014-03-31 |
2014-09-18 |
공주대학교 산학협력단 |
개 인터루킨-15 체외 증폭용 프라이머 세트, 이의 용도 및 이를 이용한 재조합 개 인터루킨-15 제조방법
|
|
CA3151221C
(en)
|
2014-06-30 |
2026-01-13 |
Altor Bioscience Corporation |
Il-15-based molecules and methods of use thereof
|
|
WO2016060996A2
(en)
*
|
2014-10-14 |
2016-04-21 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
JP7185530B2
(ja)
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス， インコーポレイテッド |
免疫細胞機能を促進するための方法および組成物
|
|
CN110214147A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
IL15/IL15Rα异源二聚体FC-融合蛋白
|
|
CN118562016A
(zh)
|
2016-10-21 |
2024-08-30 |
艾尔特生物科技公司 |
基于多聚体il-15的分子
|
|
CU24546B1
(es)
|
2016-12-30 |
2021-09-07 |
Ct Ingenieria Genetica Biotecnologia |
Composición vacunal que comprende un mutante de la interleucina-15 humana
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
WO2018195339A1
(en)
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
JP7285828B2
(ja)
|
2017-09-05 |
2023-06-02 |
トルク セラピューティクス， インコーポレイテッド |
治療用タンパク質組成物ならびにその作製および使用方法
|
|
CU24545B1
(es)
|
2017-12-29 |
2021-09-07 |
Ct Ingenieria Genetica Biotecnologia |
Péptido antagonista de la actividad de la interleucina-15
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
KR20210003813A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
|
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
|
AU2019359475A1
(en)
|
2018-10-12 |
2021-05-20 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
KR102265430B1
(ko)
*
|
2019-08-20 |
2021-06-15 |
주식회사 케어젠 |
피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
US20250243279A1
(en)
|
2023-10-17 |
2025-07-31 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|